NASDAQ · Biotechnology · USD

First Tracks Biotherapeutics Inc (TRAXV) Stock Analysis

First Tracks Biotherapeutics Inc (TRAXV) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TRAXV

$17.06

−$0.09 (−0.55%)

Last trade May 26, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TRAXV with… →

TRAXV Key Statistics

As of May 26, 2026

Trading

Open: $17.20
Previous Close: $17.15
Day's Range: 16.21–17.80
52-Week Range: 14.79–26.80
Volume: 290.82K

Valuation

Market Cap: $782.20M

Financials (FY)

Profit margin: 0.00%

Dividend and dates

Avg Volume: 265.53K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TRAXV Valuation vs Biotechnology Median

Median of 656 stocks

Metric	TRAXV	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

First Tracks Biotherapeutics Inc (TRAXV) carries a market capitalisation of $782.20M. It is classified in the Biotechnology industry, within the Healthcare sector.

The most recent close on file for TRAXV is $17.06, dated May 26, 2026. That is −$0.09 (−0.55%) against the previous close. Over the past 52 weeks the price has ranged from $14.79 to $26.80. The latest close sits 15.31% above that 52-week low.

Financial Health

Profit margin runs at 0%.

Growth & Income

No dividend is on file for TRAXV.

So far in 2026 the price is −10.24%.

Peer Comparison

First Tracks Biotherapeutics Inc (TRAXV) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
First Tracks Biotherapeutics Inc	TRAXV	$782.20M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. First Tracks Biotherapeutics Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of May 26, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc.